appConfigEntityId

bodyType

customContents

entityId

entityUuid

isVideo

articlePageQuery

article

articleSchemaContent

content

hooksArticlePageAdvertisementConfigArticle

hooksArticlePageFloatingButtonConfigArticle

appConfig

filter

json

liveArticle

Zha Daojiong

Resumption of cooperation in public health was not highlighted as a deliverable following the recent meeting in Beijing between US and Chinese diplomats, but it deserves a concerted effort from both sides to keep up the momentum.
Days before US Secretary of State Antony Blinken’s trip, senior officials from American and Chinese drug regulatory authorities met in Beijing and “exchanged views on cooperation for 2023 and in the future”. That meeting marked an end to the suspension of contacts between the two agencies.
Two issues stand out in promoting public health cooperation between the two societies. The first is the fate of the science cooperation agreement.
Over the past four decades, collaborative projects among health scientists, universities and research laboratories in the US and China were underpinned by the 1979 bilateral Umbrella Science and Technology Agreement. Citizens of the two countries benefited as the medicinal and healthcare industries grew more intertwined.
Renewal of the agreement, set for this August, is being debated in the United States. The debate has been in the news because the last renewal, in 2018, slipped through the “maximum pressure” campaign of Donald Trump’s administration.
In the more recent years, however, government-endorsed health science cooperation has suffered from a drastic curtailment. Part of the cause is that, in the 2000s, increasing levels of US procurement of medicine – generic drugs and active pharmaceutical ingredients – from China grew to be a political issue. Ascertaining the degree of US dependence is a complex task in and of itself.
US should enhance not sever scientific ties with China
Worse still, along with concerns about dependence in supply came worries about the weaponisation of drug exports by China, which grew louder as the tit-for-tat trade tariffs and export restrictions kicked into full gear in 2019. So far, though, there is no evidence of either side treating trade in medicine or medical products as a national security issue.
However, adding to the complexity is the fact that national security has crept into what is left of collaboration among the health sectors of the two countries. As participants in the China-US Track II dialogue on healthcare wrote in their 2022 agreement, “both [the American and Chinese] governments have restricted the exchange of data and research based on data security and more broadly national security concerns, with often vague definitions of the terms”.
Still, there is no reason not to renew the agreement – all things considered, progress in medicinal and medical sciences ought to prevail. Even during times of high tensions between the two countries, China’s status as one of the world’s most populous nations makes it a rich source of medicinal and medical data for researchers and developers in the US. This fact defies diplomatic preferences.
Equally significant for China, the Biden administration’s identification of biotech as a target for “de-risking” should not limit the space for cooperation with anyone, including the US. Good-faith negotiations towards renewal of the agreement is the right thing to do for the sake of public health protection and improvement of its own population.


The other issue has to do with the US assessment of the level of Chinese action in helping curtail the opioid epidemic in the US. Controlling the flow of fentanyl precursors from China is a standard topic in the US political arena.
China first instituted regulations on fentanyl use and export in 1996. In 2015, it included six fentanyl analogues and 110 other pharmaceutical chemicals in its list of controlled substances, and imposed controls on four more fentanyl analogues and fentanyl-related chemicals in 2018.
In November 2019, US and Chinese drug law-enforcement agencies jointly uncovered a fentanyl smuggling case, which ended in a trial of wrongdoers in Xingtai, Hebei province. This took place against the backdrop of generally low levels of cooperation between the governments.
As US Ambassador to China Nicholas Burns said last month in reference to the flow of fentanyl, “the government here in Beijing is not contributing to that problem”. The task is to strengthen international cooperation to punish black market firms in China and transnational criminal networks that ship illicit precursor chemicals and products to the US.
The Chinese suppliers fuelling America’s fentanyl epidemic
Such cooperation is not a favour from China for the US. On the contrary, knowledge gained about challenges within the US on opioid regulation and treatment can be valuable for Chinese public health practitioners and regulators.
Future discussions among Chinese and Americans concerned about the state of relations should make opioids – fentanyl in particular – a focus and involve experts in medical research, pharmaceutical production and trade, and public health. Such exchanges should also aim at a shared understanding of the cross-border movement of chemical precursors, the manufacturing of medicine for pain relief and illicit transborder flows.
Last, but not least, the thaw in government-to-government contacts between China and the US, however tentative, is premised on the protection of their people’s welfare. For both countries, there is every reason to make renewal of the science agreement and enhancement of dialogue on addressing the misuse of fentanyl and other opioids a manifestation of people-centred diplomacy.
Zha Daojiong is a professor in the School of International Studies and Institute of South-South Cooperation and Development, Peking University. He is also a participant of the China-US healthcare track II dialogue


Giant pandas Ping Ping and Fu Shuang touch down in the US under new loan deal

Keep out: why Greenland is the US military’s new eyes in the Arctic on China

From body language to ping-pong, decoding the symbolism during Xi and Trump’s meeting

How Kenya’s sacred Mrima Hill became new front in US-China minerals rivalry

US-China relations

No reason US and China can’t renew cooperation in health sciences and combating opioid misuse

A US Drug Enforcement Administration chemist checks confiscated pills containing fentanyl at a laboratory in New York. Future discussions among Chinese and Americans concerned about the state of relations should make opioids – fentanyl in particular – a focus. Photo: AFP

China and US revive drug control talks in lead-up to Blinken trip

Fentanyl overdoses kill thousands of people in the US each year. Photo: Reuters

US sanctions Chinese, Mexican entities for enabling counterfeit, fentanyl-laced pill production

A bag of heroin fentanyl pills. File photo:  US Drug Enforcement Administration via TNS

US drug shortages could worsen in coming months because of China’s health crisis, expert says

Workers at a medical manufacturer’s factory in Beijing in December. Drug shortages in the United States may worsen as China battles its Covid-19 surge. Photo: China Daily via Reuters

The Food and Drug Administration lists roughly 120 treatments in short supply in the US. Photo: AP

US scientists keep ties with Chinese peers despite crackdown: researcher

Around 42 per cent of Chinese scientists in the US said they felt racially profiled by the US government, according to a survey from last year.
Photo: Shutterstock

Opinion

News

China

Diplomacy

China’s vast population makes it a rich source of medicinal and medical data for researchers and developers in the US
Meanwhile, knowledge gained about America’s challenges on opioid regulation and treatment can be valuable for Chinese public health authorities


China’s vast population makes it a rich source of medicinal and medical data for researchers and developers in the US. Meanwhile, knowledge gained about America’s challenges on opioid regulation and treatment can be valuable for Chinese public health authorities.


Fentanyl and other opioids

Drugs

Science

Expresses the views, ideas and conclusions of the author. (Eg. Enough of Crazy Rich Asians, think of crazy poor Hongkongers.)
